{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:12:00Z","timestamp":1787962320347,"version":"build-2784847793"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1136\/ard.2004.023408","type":"journal-article","created":{"date-parts":[[2004,6,19]],"date-time":"2004-06-19T00:13:41Z","timestamp":1087604021000},"page":"207-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"title":["Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities"],"prefix":"10.1016","volume":"64","author":[{"given":"Y","family":"Yazici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Sokka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kautiainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Swearingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Kulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Pincus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2004.023408_bib1","first-page":"2521","article-title":"Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients","volume":"29","author":"Sokka","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.023408_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/rheumatology\/28.2.147","article-title":"Prospective long term followup of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression","volume":"28","author":"Hanrahan","year":"1989","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2004.023408_bib3","first-page":"1323","article-title":"Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases","volume":"18","author":"Sany","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.023408_bib4","first-page":"978","article-title":"The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: An open prospective study","volume":"18","author":"Mielants","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.023408_bib5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/ard.54.9.708","article-title":"Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients","volume":"54","author":"Alarcon","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.023408_bib6","first-page":"1881","article-title":"Longterm treatment of destructive rheumatoid arthritis with methotrexate","volume":"24","author":"Rau","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.023408_bib7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/1529-0131(200001)43:1<14::AID-ANR3>3.0.CO;2-7","article-title":"Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis","volume":"43","author":"Krause","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.023408_bib8","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/ard.2004.023408_bib9","first-page":"1874","article-title":"Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices. I. Nonsteroidal anti-inflammatory drugs","volume":"19","author":"Pincus","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.023408_bib10","first-page":"1586","article-title":"Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: is it time to update the guidelines?","volume":"29","author":"Yazici","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.023408_bib11","doi-asserted-by":"crossref","first-page":"833","DOI":"10.7326\/0003-4819-121-11-199412010-00002","article-title":"Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis","volume":"121","author":"Morgan","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2004.023408_bib12","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1002\/art.11277","article-title":"Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events","volume":"48","author":"Yazici","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.023408_bib13","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remission in acute leukemia in children produced by folic acid antagonist 4-amethopteroylglutamicacid (aminopterin)","author":"Farber","year":"1948","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2004.023408_bib14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/ar419","article-title":"Molecular action of methotrexate in inflammatory diseases","volume":"4","author":"Chan","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1136\/ard.2004.023408_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.023408_bib16","first-page":"994","article-title":"Termination of slow acting anti-rheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts","volume":"17","author":"Wolfe","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.023408_bib17","first-page":"1885","article-title":"Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second-line drugs and prednisone","volume":"19","author":"Pincus","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.023408_bib18","unstructured":"Physicians' Desk Reference. Montvale, NJ: Thomson PDR 2003."},{"key":"10.1136\/ard.2004.023408_bib19","first-page":"1180","article-title":"Methotrexate-induced liver abnormalities in rheumatoid arthritis","volume":"16","author":"Bridges","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.023408_bib20","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0002-9343(88)80019-6","article-title":"Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis","volume":"85","author":"Shergy","year":"1988","journal-title":"Am J Med"},{"key":"10.1136\/ard.2004.023408_bib21","first-page":"489","article-title":"Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate","volume":"16","author":"Rau","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.023408_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/anr.1780320202","article-title":"Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy: a prospective study with baseline and sequential biopsy samples","volume":"32","author":"Kremer","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.023408_bib23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/art.1780380306","article-title":"The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate","volume":"38","author":"Bergquist","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.023408_bib24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000248822","article-title":"Methotrexate-induced liver cirrhosis: a follow-up","volume":"75","author":"Zachariae","year":"1987","journal-title":"Dermatologica"},{"key":"10.1136\/ard.2004.023408_bib25","first-page":"S428","article-title":"Methotrexate, laboratory testing and risk of serious illness: analyses in 20 000 patients","volume":"48","author":"Cartwright","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"Suppl.1","key":"10.1136\/ard.2004.023408_bib26","first-page":"28","article-title":"The \u201cside effects\u201d of rheumatoid arthritis: joint destruction, disability and early mortality","volume":"32","author":"Pincus","year":"1993","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2004.023408_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7326\/0003-4819-120-1-199401010-00005","article-title":"Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures","volume":"120","author":"Pincus","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2004.023408_bib28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.1780370304","article-title":"Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity","volume":"37","author":"Kremer","year":"1994","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724431269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724431269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2004.023408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:55:28Z","timestamp":1737359728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724431269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S0003496724431269"],"URL":"https:\/\/doi.org\/10.1136\/ard.2004.023408","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2004.023408","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Copyright 2005 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}